56 results about "Anti-infective therapy" patented technology

Decreasing the expression of genes in a mammalian subject has multiple applications ranging from cancer therapy to anti-infective therapy or treatment of autosomal dominant genetic disorders. Yet, there is still a lack of efficient technologies to achieve that goal in mammalian subjects in vivo. The present invention relates to methods for decreasing gene expression by administering to a mammalian subject a recombinant adeno-associated viral vector in vivo with said vector comprising an RNA interference (RNAi) expression cassette whose RNA expression products directly or indirectly lead to a decrease in expression of the corresponding RNAi target gene. Upon successful transduction with the recombinant adeno-associated viral vector, the RNA expression products of the RNAi expression cassette will decrease the cellular concentration of the mRNA transcripts of the RNAi target gene, thus resulting in decreased concentration of the protein encoded by the RNAi target gene.

The invention relates to an easily soluble antibacterial drug agent, making method and application, which consists of component A and component B with weight ratio at 100:0. 1 to 1:10, wherein the component A is piperacilliin or other physiological medicinal salt or hydrate, or tazobactam or other physiological medicinal salt or hydrate or the composition of piperacilliin or other physiological medicinal salt or hydrate and tazobactam or other physiological medicinal salt or hydrate, and the component B is pharmacy Lewis acid or Lewis base comprising soluble alkaline metals or salt of alkaline-earth metal, soluble organic base, organic acid or one or some kinds of salt of the both. The invention has merits of good water-solubility to solve fast and extend solubility, which is fit for anti-infectious treatment and precaution of bacillary diseases to human and animals.

The invention discloses a method for detecting pathogenic bacteria of pulmonary infection by a visualized gene chip, comprising the following steps: S1 determining the spectrum of pathogenic bacteria of pulmonary infection based on clinical practice; S2 making the detection target according to the specific gene of the bacteria; S3 designing general primers and probes S4 chip preparation; S5 target gene amplification; S6 chip hybridization and washing; S7 gene chip visual detection; S8 optimization conditions, establishment of methods; S9 clinical verification; S10 comparison with bacterial culture; Chip detection. Beneficial effects of the present invention: realize rapid, sensitive, and high-throughput detection of important pathogenic microorganisms of common clinical respiratory infection flora, provide evidence for clinical disease diagnosis and anti-infection treatment of acute and severe respiratory infectious diseases; provide emergency, prevention and control Provide effective and efficient screening means and methods.

The invention discloses a subacid electrolyzed oxidizing water gynecological anti-infection treatment facility. The subacid electrolyzed oxidizing water gynecological anti-infection treatment facility comprises a controller, a treatment contact component, a subacid electrolyzed oxidizing water generation device and an atomization assembly; a water pressure reducing valve is additionally arranged on the subacid electrolyzed oxidizing water generation device on the basis of original oxidation reduction potential water so as to control the water inlet flow, a brine pump is additionally arranged so as to adjust the circulation stroke frequency, and therefore subacid water with the PH value ranging from 3.5 to 5.5, the oxidation reduction potential (ORP) ranging from +800 mV to +1000 mV and the available chlorine content ranging from 80 mg/L to 150 mg/L is generated; and then the atomization assembly and the treatment contact component are additionally arranged so as to meet the requirements of female genital tract anti-infection treatment. The application limit that a traditional subacid electrolyzed oxidizing water generation device is only used in the disinfection field is overcome, and a new gynecological anti-infection physical treatment scheme which is wide in antibacterial spectrum, rapid in sterilization, non-toxic and free of stimulation, is favorable for maintaining a genital tract acid environment, and is favorable for genital tract micro-ecological environment reconstruction is provided for clinic.

The invention relates to a method for promoting macrophages to polarize to M1 type by utilizing a piezoelectric effect and application. According to the method, a piezoelectric material is combined with ultrasound to trigger non-contact and non-invasive electrical stimulation, and the important role of the electrical stimulation in immune regulation is verified; by taking the piezoelectric material as a cell culture substrate, and combining with ultrasound stimulation, M1 type polarized macrophages are cultured in vitro, and compared with a common biochemical method, the method does not need to introduce external polarized macrophages (PMAPs); and by utilizing the commercialized piezoelectric material, macrophages can be rapidly promoted to polarize to the M1 type by a method for applyingthe ultrasound; The method has a good effect of promoting the macrophages to polarize to the M1 type by utilizing the piezoelectric effect, and has the clinical application potential of tumor immunotherapy and anti-infective therapy. The method disclosed by the invention can be used for producing the M1 type polarized macrophages in batches so as to promote application of the piezoelectric material in immunotherapy.

The invention relates to the technical field of medicine, and provides application of luteolin in a bacterial quorum sensing inhibition system, application of luteolin in preparing drug for lowering pathogenicity of staphylococcus aureus virulence factors and application of luteolin in preparing drug for inhibiting transcription of hla and agrA genes of staphylococcus aureus. Minimum effective concentration with application value is provided for the application of luteolin in the bacterial quorum sensing inhibition system, and a reference is provided for medically preparing specific bio-film forming inhibitors. The invention further provides a drug combination for inhibiting formation of staphylococcus aureus bio-films. The drug combination contains luteolin. According to the drug combination, formation of the bio-films of staphylococcus aureus can be inhibited by effectively inhibiting a quorum sensing system of staphylococcus aureus through tiny luteolin, prognosis risk, of staphylococcus aureus, for infection with high-drug-tolerance bio-films in anti-infection treatment is lowered, and a valuable reference is provided for medically preparing specific preparations for inhibiting the staphylococcus aureus bio-films.

The invention discloses an application of liquiritin in preparing an escherichia coli fluoroquinolone efflux pump inhibitor. Research results indicate that, the liquiritin can obviously reduce the minimal inhibitory concentration of fluoroquinolone of drug-resistant escherichia coli (fluoroquinolone active efflux phenotype and acrA gene high expression strain), obviously increase drug accumulation concentration in a thallus, and obviously reduce expression quantity of an efflux pump gene acrA, so that susceptibility of the drug-resistant escherichia coli to the fluoroquinolone is increased, usage amounts of drugs are reduced, treatment cost is reduced, and food safety problems such as drug residues are decreased. Simultaneously, the liquiritin is a natural compound existing in plants, has no side effects such as teratogenesis and carcinogenesis, and is safe and nontoxic. The invention not only broadens application fields of the liquiritin and improves market value of the liquiritin, but also provides an efficient and safe bacteria efflux pump inhibitor for anti-infective therapy.

The invention provides a combination of cefoperazone sodium and sulbactam sodium. The combination consists of the cefoperazone sodium and the sulbactam sodium, and the weight ratio of which is 3 to 1. The combination of cefoperazone sodium and sulbactam sodium of the invention has the comparative curative effect at the aspect of antibacterial effect with a compound preparation of 1 to 1 or 2 to 1 of the cefoperazone sodium/the sulbactam sodium in markets. The invention reduces the corresponding content of the sulbactam sodium in the combination, so the invention has wider clinical application range and can reduce the production cost of the drug. Compared with the prior compound preparation of the cefoperazone sodium/the sulbactam sodium, the invention is characterized by being fit for the anti-infection remedy of the patient with the renal dysfunction and the remedy of the seriously infected patient.

Described is a method for the generation of antigen-presenting cells (APC), preferably bone marrow-derived dendritic cells (BMDC) or peripheral blood-derived dendritic cells, as antigen carrier having immunostimulatory properties for anti-infective treatment comprising the steps of (a) pulsing the APC with antigen and (b) treating the APC with a CpG oligonucleotide. Said APC are useful as an immune prophylactic or immune therapeutic agent against diseases like AIDS, tuberculosis, malaria or leishmaniasis.

The invention belongs to the field of biomedicine, and mainly relates to an antibacterial peptide and antibiotic combined antibacterial drug and a use method thereof. The invention aims to provide a novel effective choice for the anti-infective therapy, and provides an antibacterial drug. The antibacterial drug comprises main active components: antibacterial peptide and antibiotic. The drug can effectively improve the antibacterial effect. The using amount of drugs, in particular antibiotics, is reduced; the side effect and toxic effect are reduced therefore; the drug resistance of strains is effectively reduced; the killing effect on drug resistant strains is also very good, and a novel effective choice is provided for anti-infective therapy.

Disclosed is an imine-resistant bacillus pyocyaneus bacteriophage and its use for treating infection, wherein a stain of broad-spectrum drug-resistant bacillus pyocyaneus bacteriophage phiA392, which can effectively kill drug-resistant bacillus pyocyaneus in vivo and in vitro, the bacteriophage can decompose multiple strains of clinically segregated imipenem-resistant bacillus pyocyaneus in vivo. The invention proves the superiority and feasibility of bacteriophage as a therapeutic substance in the clinical application to the treatment of bacillus pyocyaneus resistant affection, and provides a novel therapeutic means for clinical imipenem-resistant bacillus pyocyaneus affection.

The invention discloses a specific primer combination and a probe combination for detecting four glycopeptide drug resistance genes vanA, vanB, vanD and vanM in enterococcus bacteria, comprising a primer combination for specific amplification of four glycopeptide drug resistance genes and further comprising specific probes for detecting the four glycopeptide drug resistance genes. A method for detecting the four glycopeptide drug resistance genes by using the specific primer and probe combinations is further provided. The combinations have high specificity and coverage, can be used not only for detecting the drug resistance genes vanA, vanB, vanD and vanM in human infected samples but also for suggesting resistance degree to vancomycin and teicoplanin, and provides a reference basis for clinical anti-infective therapy medication. At the same time, the development of glycopeptides drug resistance is monitored. The combinations can also be used for monitoring the distribution and transfer of the four glycopeptide drug resistance genes in animal and environmental samples.

The present invention relates to riminophenazines having heteroaromatic substitutions, including those with 2-heteroaryl-amino substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.

The invention discloses a common fifty-five respiratory tract pathogen high-throughput identification and detection method which comprises the following steps: detecting whether a target nucleic acidexists or not only by detecting whether a single base extension reaction occurs at a polymorphic site or not without determining the base type of the polymorphic site so as to judge whether a sample target pathogen exists or not; the method specifically comprises the following steps: multiplex PCR, single base extension reaction and mass spectrum detection. The method has the beneficial effects that the diagnosis efficiency is improved, the method is not prone to cross contamination, the test operation is simple and convenient, standardization is easy, and various common respiratory virus nucleic acids in clinical specimens can be rapidly detected at the same time. High-throughput differential diagnosis is carried out on the common respiratory tract pathogens so that the pathogens can be clarified clinically as soon as possible, and the method has important significance in targeted anti-infection treatment.

The invention provides a nano-silver emulsifiable paste and its preparation method and relates to the field of medicines. The nano-silver emulsifiable paste is an O/W type emulsifiable paste or W/O type emulsifiable paste which is prepared by a certain preparation technology with nano-silver being used as a main drug. The nano-silver emulsifiable paste can be used for treating infection of infected wounds and body surface chronic ulcer (venous ulcer, pressure ulcer and the like) caused by burn and scald and physical and mechanical damage and for promoting healing of the wounds. The O/W type emulsifiable paste is similar to a moistening burn cream and can provide burn and scald wounds with a moistening environment which is beneficial to tissue regeneration. Simultaneously, due to specific high antibacterial activity and good wound heating promotion effect of the nano-silver, the nano-silver emulsifiable paste is better than the moistening burn cream; and in comparison with sulfadiazine silver and other external-use anti-infection drugs, the nano-silver emulsifiable paste is beneficial to wound healing, has no bacterial drug resistance and has high antibacterial activity.

A transduction peptide-humanized granulocyte colony stimulating factor fusion protein, nucleic acid molecule of nucleic acid sequence for encoding fusion protein, expression carrier containing the nucleic acid molecule and its usage of fusion protein in preparation of medicine are disclosed. It can be used for neutrophil reduction after tumor radiant chemo-radiotherapy, hematopoietic restoration after bone marrow transplantation, peripheral blood stem cells mobilization, anti-infective therapy, aregenerative anemia, systemic lupus erythematosus and immune response adjustment.

The present invention relates to oxidase-like activity of nitrogen-doped carbon nanospheres and uses thereof, in particular to oxidase-like activity of nitrogen-doped carbon nanospheres and uses thereof in tumor treatment, anti-infection treatment and sewage treatment.

The invention provides an antibiotic hydrogel capable of degrading a biofilm. The antibiotic hydrogel is formed by crosslinking oxidized polysaccharide macromolecules, biological enzymes capable of degrading the biofilm and aminoglycoside antibiotics through acid-sensitive Schiff base bonds. The invention further provides antibacterial application of the antibiotic hydrogel capable of degrading the biofilm in vitro and in vivo. According to the antibiotic hydrogel capable of degrading the biofilm provided by the invention, on one hand, the aminoglycoside antibiotics can be released as required; and on the other hand, a biological enzyme component for degrading biofilm matrix is released at the same time, the biofilm is destroyed, the sensitivity of aminoglycoside antibiotics for treating biofilm infection is improved, and the biofilm is expected to be applied to various clinical anti-infection treatments.

The invention relates to the technical field of biological medicine, in particular to a preparation method of a levofloxacin hydrochloride dropping pill. The dropping pill contains the following pharmaceutical grade components of PEG-4000, PEG-6000 and levofloxacin hydrochloride fine powder, wherein the mass ratio of the materials in the prescription is (0.4-0.8) : (0.4-0.8) : (0.2-0.4) in sequence. According to a new dosage form of levofloxacin hydrochloride, except that acute infectious diseases need intravenous injection of a levofloxacin hydrochloride injection, the anti-infective therapyof other adaptation diseases all can select the levofloxacin hydrochloride dropping pill with quicker effects.

The invention relates to application of 20(S)-ginsenoside Rh2 in preparation of drugs enhancing antibacterial action of 4-quinolones. The invention discloses that 20(S)-ginsenoside Rh2 can improve the therapeutic effect of ciprofloxacin on a mouse abdominal infection model, and can reduce the minimal inhibitory concentration (MIC) of ciprofloxacin in staphylococcus aureus ATCC 29213, 4 staphylococcus aureus clinical strains, and pseudomonas aeruginosa ATCC 27853. On a staphylococcus aureus invaded THP-1 macrophage model, 20(S)-ginsenoside Rh2 can enhance the intracellular antibacterial action of levofloxacin. Therefore, 20(S)-ginsenoside Rh2 is expected to be used for preparing a synergist of quinolone antibiotics, and can be developed into assistant drugs of anti-infective therapy.

The invention discloses a medicine for treating damp-heat stasis syndrome of liver cirrhosis spontaneous bacterial peritonitis and a preparation method thereof, and aims to solve the technical problems of liver and kidney function damage and gradually increased drug resistance rate in western medicine anti-infection treatment. The medicine is mainly prepared from fructus polygoni orientalis, verbena, rheum officinale, lalang grass rhizome, pinellia ternate, coptis chinensis, scutellaria baicalensis, codonopsis pilosula, rhizoma zingiberis, liquorice and the like. The medicine is scientific and reasonable in compatibility, has good effects of clearing heat and promoting diuresis, eliminating mass and removing stasis, and detoxifying and relaxing bowels, focuses on removing damp-heat stasis toxin and excess evil, also can be used for nourishing vital energy, and combining tonification and purgation, so that Qi, blood and water are harmonized, and various symptoms are reduced; and the medicine can be used for effectively treating damp-heat stasis syndrome type spontaneous bacterial peritonitis, and is rich in raw material source, convenient to take, relatively low in cost, safe and free of toxic or side effect.

The invention belongs to the technical field of biomarkers, and particularly discloses application of GSDMD as a biomarker in differential diagnosis and curative effect evaluation of pleural effusion related diseases. It is found for the first time that the GSDMD level is remarkably increased in pleural fluid caused by tuberculous pneumonia, pulmonary infection and pulmonary malignant tumors, and the GSDMD is a reliable biomarker for differential diagnosis of lung diseases; meanwhile, the GSDMD level is remarkably related to the anti-infection treatment effect of the lung diseases. By quantitatively analyzing the GSDMD level of pleural effusion, an objective basis can be provided for early judgment of common lung diseases, and an objective basis can be provided for formulating a reasonable treatment scheme for lung anti-infection treatment. On the working basis of the invention, a corresponding GSDMD detection kit can be directly transformed and developed, so as to carry out early differential diagnosis and curative effect evaluation on pleural effusion related diseases. The GSDMD has good clinical application value.